^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

ALK translocation

i
Other names: NBLST3, CD246, Anaplastic Lymphoma Kinase, Anaplastic Lymphoma Kinase (Ki-1), CD246 Antigen, Mutant Anaplastic Lymphoma Kinase, ALK, ALK Receptor Tyrosine Kinase, Anaplastic Lymphoma Receptor Tyrosine Kinase, ALK Tyrosine Kinase Receptor
Entrez ID:
Related tests:
Phase 3
National Cancer Institute (NCI)
Recruiting
Last update posted :
06/13/2024
Initiation :
11/11/2024
Primary completion :
06/01/2026
Completion :
06/01/2026
EGFR • PD-L1 • ALK
|
ALK translocation • EGFR negative
|
Keytruda (pembrolizumab) • carboplatin • albumin-bound paclitaxel • pemetrexed • Pemfexy (pemetrexed)
Phase 1/2
National Cancer Institute (NCI)
Recruiting
Last update posted :
06/07/2024
Initiation :
06/29/2015
Primary completion :
12/30/2024
Completion :
12/30/2025
EGFR • HER-2 • BRAF • ALK • PGR • BRCA1 • BRCA2
|
BRAF V600E • BRCA2 mutation • BRCA1 mutation • EGFR mutation • BRAF V600 • ALK translocation • BRCA1 mutation + BRCA2 mutation
|
Lynparza (olaparib) • Imfinzi (durvalumab) • Recentin (cediranib)
Phase 3
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
06/07/2024
Initiation :
04/05/2019
Primary completion :
12/31/2028
Completion :
12/31/2028
EGFR • PD-L1 • BRAF • ALK • ROS1
|
PD-L1 expression • EGFR mutation • BRAF mutation • BRAF V600 • ALK translocation
|
Keytruda (pembrolizumab) • carboplatin • pemetrexed • Pembroria (pembrolizumab biosimilar) • Pemfexy (pemetrexed)
Phase 1
M.D. Anderson Cancer Center
Recruiting
Last update posted :
06/04/2024
Initiation :
12/01/2020
Primary completion :
09/03/2025
Completion :
09/03/2025
ALK • MET • BRCA1 • BRCA2 • ROS1 • RAD51C • RAD51D
|
MET amplification • MET mutation • MET expression • ALK translocation
|
Xalkori (crizotinib) • Ibrance (palbociclib) • Talzenna (talazoparib) • Inlyta (axitinib)
Phase 1/2
Advaxis, Inc.
Completed
Last update posted :
06/04/2024
Initiation :
02/12/2019
Primary completion :
02/22/2022
Completion :
02/22/2022
EGFR • PD-L1 • ALK
|
PD-L1 expression • EGFR mutation • ALK translocation
|
Keytruda (pembrolizumab) • ADXS-503
Phase 1
ModernaTX, Inc.
Recruiting
Last update posted :
06/04/2024
Initiation :
08/14/2017
Primary completion :
06/30/2025
Completion :
06/30/2025
EGFR • ALK • TMB
|
EGFR mutation • ALK positive • ALK translocation • EGFR positive
|
Keytruda (pembrolizumab) • mRNA-4157 • pembrolizumab subcutaneous (MK-3475 SC)
Phase 1/2
Triumvira Immunologics, Inc.
Recruiting
Last update posted :
05/22/2024
Initiation :
08/23/2023
Primary completion :
08/01/2027
Completion :
08/01/2027
EGFR • HER-2 • BRAF • ALK • CLDN18 • BRCA
|
EGFR mutation • BRAF mutation • HER-2 expression • CLDN18.2 positive • ALK translocation • BRCA mutation • CLDN18 fusion
|
albumin-bound paclitaxel • cyclophosphamide • TAC101-Claudin18.2
Phase N/A
University of Washington
Recruiting
Last update posted :
05/08/2024
Initiation :
09/26/2019
Primary completion :
11/30/2026
Completion :
11/30/2026
EGFR • PD-L1 • BRAF • ALK • ROS1
|
EGFR mutation • BRAF mutation • ALK translocation
Phase 1/2
Pfizer
Active, not recruiting
Last update posted :
05/03/2024
Initiation :
03/18/2020
Primary completion :
03/03/2022
Completion :
01/17/2025
EGFR • PD-L1 • BRAF • ALK • ROS1
|
PD-L1 expression • EGFR mutation • BRAF mutation • ALK translocation
|
sasanlimab (PF-06801591)
Phase 2
Sidney Kimmel Comprehensive Cancer Center at Jo...
Completed
Last update posted :
05/03/2024
Initiation :
11/06/2013
Primary completion :
04/04/2023
Completion :
04/04/2023
EGFR • KRAS • ALK
|
EGFR mutation • EGFR exon 19 deletion • ALK positive • ALK rearrangement • EGFR wild-type • ALK wild-type • ALK translocation
|
Opdivo (nivolumab) • azacitidine • Jingzhuda (entinostat) • Onureg (azacitidine oral)
Phase 2
City of Hope Medical Center
Recruiting
Last update posted :
05/02/2024
Initiation :
06/01/2024
Primary completion :
01/02/2028
Completion :
01/02/2028
EGFR • PD-L1 • ALK
|
EGFR mutation • ALK translocation
|
Libtayo (cemiplimab-rwlc)
Phase 2
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Recruiting
Last update posted :
05/01/2024
Initiation :
07/15/2022
Primary completion :
05/29/2027
Completion :
12/26/2027
EGFR • PD-L1 • ALK
|
ALK translocation • EGFR negative
|
Inlyta (axitinib) • erfonrilimab (KN046)
Phase 1/2
Merck Sharp & Dohme LLC
Completed
Last update posted :
04/16/2024
Initiation :
07/02/2017
Primary completion :
04/08/2024
Completion :
04/08/2024
EGFR • BRAF • ALK • CTLA4
|
BRAF V600E • BRAF V600 • ALK translocation
|
Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • quavonlimab (MK-1308) • quavonlimab/pembrolizumab (MK-1308A)
Phase 2
Rutgers, The State University of New Jersey
Recruiting
Last update posted :
04/10/2024
Initiation :
04/28/2022
Primary completion :
05/01/2025
Completion :
12/01/2025
EGFR • PD-L1 • BRAF • ALK • MET • ROS1
|
PD-L1 expression • EGFR mutation • BRAF mutation • BRAF V600 • MET exon 14 mutation • MET mutation • ALK translocation
|
Keytruda (pembrolizumab) • carboplatin • 5-fluorouracil • albumin-bound paclitaxel • pemetrexed
Phase 1
NYU Langone Health
Recruiting
Last update posted :
03/29/2024
Initiation :
08/01/2023
Primary completion :
08/01/2025
Completion :
08/01/2026
KRAS • ALK • RET • ROS1
|
KRAS mutation • KRAS G12C • ALK rearrangement • KRAS G12 • ALK translocation
|
Lumakras (sotorasib) • ladarixin (DF-2156A)
Phase 2
NYU Langone Health
Withdrawn
Last update posted :
03/29/2024
Initiation :
04/01/2024
Primary completion :
04/01/2025
Completion :
04/01/2026
KRAS • ALK • RET • ROS1
|
KRAS mutation • KRAS G12C • ALK rearrangement • KRAS G12 • ALK translocation
|
Lumakras (sotorasib) • ladarixin (DF-2156A)
Phase 2
Massachusetts General Hospital
Completed
Last update posted :
03/29/2024
Initiation :
12/01/2014
Primary completion :
11/10/2021
Completion :
11/01/2022
EGFR • ALK • ROS1
|
EGFR mutation • ALK translocation
|
Opdivo (nivolumab) • Yervoy (ipilimumab)
Phase 1/2
NeoImmuneTech
Active, not recruiting
Last update posted :
03/15/2024
Initiation :
06/10/2020
Primary completion :
11/05/2024
Completion :
03/31/2025
BRAF • ALK • ROS1
|
EGFR mutation • BRAF mutation • ALK translocation • ROS1 mutation
|
Keytruda (pembrolizumab) • Hyleukin-7 (efineptakin alfa)
Phase 1
Boehringer Ingelheim
Active, not recruiting
Last update posted :
03/05/2024
Initiation :
05/04/2017
Primary completion :
05/31/2023
Completion :
05/30/2024
HER-2 • ER • ALK • PGR
|
EGFR mutation • HER-2 negative • ALK translocation
|
Verzenio (abemaciclib) • fulvestrant • letrozole • anastrozole • xentuzumab (BI-836845)
Phase 1/2
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
03/05/2024
Initiation :
07/30/2015
Primary completion :
02/24/2021
Completion :
10/30/2025
EGFR • ALK
|
EGFR mutation • ALK translocation
|
berzosertib (M6620) • topotecan
Phase N/A
Pfizer
No Longer Available
Last update posted :
03/04/2024
ALK • MET • ROS1 • NTRK3 • ETV6
|
NTRK3 fusion • ALK mutation • ETV6-NTRK3 fusion • ALK translocation
|
Xalkori (crizotinib)
Phase 2
UNICANCER
Completed
Last update posted :
02/28/2024
Initiation :
08/01/2013
Primary completion :
06/01/2019
Completion :
12/06/2023
ALK • MET • ROS1
|
ALK positive • MET overexpression • ALK translocation
|
Xalkori (crizotinib)
Phase 3
ImmunityBio, Inc.
Active, not recruiting
Last update posted :
02/07/2024
Initiation :
05/18/2018
Primary completion :
10/01/2025
Completion :
04/01/2026
EGFR • PD-L1 • BRAF • ALK • ROS1 • NTRK
|
PD-L1 expression • EGFR mutation • BRAF mutation • ALK translocation
|
Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • Anktiva (nogapendekin alfa inbakicept-pmln)
Phase 1/2
Sotio Biotech Inc.
Recruiting
Last update posted :
01/11/2024
Initiation :
05/18/2022
Primary completion :
04/01/2026
Completion :
12/01/2041
EGFR • ALK • BRCA • GPC3
|
EGFR mutation • ALK translocation • BRCA mutation • GPC3 expression • GPC3 overexpression
|
cyclophosphamide • BOXR1030
Phase 2
Wake Forest University Health Sciences
Completed
Last update posted :
01/05/2024
Initiation :
06/17/2016
Primary completion :
11/19/2022
Completion :
12/28/2022
EGFR • PD-L1 • ALK • ROS1
|
EGFR mutation • ALK rearrangement • ALK translocation
|
Keytruda (pembrolizumab) • carboplatin • paclitaxel
Phase 3
Merck Sharp & Dohme LLC
Completed
Last update posted :
12/22/2023
Initiation :
09/07/2016
Primary completion :
09/09/2019
Completion :
10/14/2022
EGFR • PD-L1 • ALK
|
PD-L1 expression • EGFR mutation • ALK translocation
|
Keytruda (pembrolizumab) • docetaxel
Phase 3
UNICANCER
Recruiting
Last update posted :
12/18/2023
Initiation :
03/21/2019
Primary completion :
09/21/2026
Completion :
09/21/2026
EGFR • ALK
|
EGFR mutation • ALK positive • ALK translocation
|
Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed
Phase 2
Sheba Medical Center
Recruiting
Last update posted :
11/21/2023
Initiation :
12/09/2021
Primary completion :
12/01/2026
Completion :
12/01/2026
EGFR • ALK • ROS1
|
EGFR mutation • ALK rearrangement • ALK translocation
|
Imfinzi (durvalumab) • Imjudo (tremelimumab)
Phase 2
NovoCure GmbH
Recruiting
Last update posted :
10/06/2023
Initiation :
07/12/2021
Primary completion :
07/01/2024
Completion :
12/01/2026
EGFR • PD-L1 • ALK
|
PD-L1 expression • ALK translocation
|
Keytruda (pembrolizumab)
Phase 2
CrystalGenomics, Inc.
Recruiting
Last update posted :
08/30/2023
Initiation :
08/23/2023
Primary completion :
08/01/2026
Completion :
12/01/2026
EGFR • ALK
|
EGFR mutation • ALK translocation
|
carboplatin • AiRuiKa (camrelizumab) • pemetrexed
Phase 1
Tesaro, Inc.
Recruiting
Last update posted :
08/22/2023
Initiation :
03/07/2016
Primary completion :
05/15/2026
Completion :
10/27/2027
EGFR • ALK • MSI • MLH1 • MSH6 • MSH2
|
EGFR mutation • MSI-H/dMMR • ALK translocation • MSH6 expression
|
Jemperli (dostarlimab-gxly)
Phase N/A
Intergroupe Francophone de Cancerologie Thoracique
Completed
Last update posted :
07/21/2023
Initiation :
04/01/2012
Primary completion :
04/01/2013
Completion :
04/01/2013
HER-2 • KRAS • BRAF • ALK • EML4 • RAS • PI3K
|
KRAS mutation • BRAF mutation • HER-2 mutation • RAS mutation • ALK translocation
Phase 1
iOnctura
Active, not recruiting
Last update posted :
06/29/2023
Initiation :
02/25/2020
Primary completion :
09/01/2023
Completion :
04/01/2024
PD-L1 • BRAF • ALK • ROS1 • MSLN
|
BRAF mutation • BRAF V600 • ALK translocation
|
cisplatin • Bavencio (avelumab) • Jakafi (ruxolitinib) • pemetrexed • roginolisib (IOA-244)